Riskpilot← Back to searchSign inGet full accessPromegranate Veterinary AB
ABActiveOrg 5592909690Malmavägen 13Research and experimental development on natural sciences and engineering · NACE 7210Est. 20200 employees
Revenue 2024
SEK 610K
+224% vs 2023
EBITDA margin
98.4%
+227% vs 2023
Equity ratio
61.5%
Financial strength
Net profit 2024
SEK 384K
+159% vs 2023
| Revenue | SEK 610K | +224% |
| EBITDA | SEK 600K | +227% |
| Net profit | SEK 384K | +159% |
| Total assets | SEK 1M | +220% |
| Equity | SEK 629K | +157% |
| Employees | 0 | — |
Legal name
Promegranate Veterinary AB
Org number
5592909690
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
16 december 2020
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva forskning, produktutveckling, konsultverksamhet och företagsrådgivning inom veterinärmedicin och humansjukvård, samt kennelverksamhet och därmed förenlig verksamhet.
Address
Malmavägen 13
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 38 | 62 | 188 | 610 |
| Staff expenses | — | −2 | −2 | −3 |
| EBITDA | 30 | 59 | 183 | 600 |
| Depreciation & amort. | −0 | — | — | — |
| EBIT | 30 | 59 | 183 | 600 |
| Net financials | — | 0 | 3 | 7 |
| Profit before tax | 31 | 60 | 186 | 482 |
| Tax | −7 | −12 | −38 | −98 |
| Net profit | 24 | 48 | 148 | 384 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 52 | 116 | 320 | 1 022 |
| Equity | 49 | 96 | 245 | 629 |
| Long-term debt | 0 | — | — | — |
| Short-term debt | 4 | 20 | 75 | 268 |
| Total debt | 4 | 20 | 75 | 268 |
EBITDA margin
98.4%
This company
15.8%
Market median
+523% vs market
20212024
Equity ratio
61.5%
This company
38.2%
Market median
+61% vs market
20212024
Return on equity
61.1%
This company
18.4%
Market median
+232% vs market
20212024
Net profit margin
63.0%
This company
8.1%
Market median
+678% vs market
20212024
Asset turnover
0.60×
This company
1.12×
Market median
-46% vs market
20212024
Debt / equity
0.62×
This company
0.62×
Market median
+0% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-12-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Former (4) | ||
| Deputy Board Member | 2021 – 2022 | |
| Deputy Board Member | 2021 – 2022 | |
| Board of Directors | 2021 – 2022 | |
| Deputy Board Member | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Promegranate Veterinary AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Nils Henrik Kristoffer Svensson | Deputy Board Member | 0 companies |
| Lina Anna Elisabeth Nordström | Deputy Board Member | 0 companies |
| Angelica Sara Ingrid Loskog | Deputy Board Member | 0 companies |
| Nina Marika Wodzinski | Board of Directors | 0 companies |
| Henrik Daniel Karlsson | Deputy Board Member | 0 companies |
| Mohammad Alimohammadi | Board of Directors | 0 companies |